B. Chowbay

Pharmacology · 2009

A researcher in the Science corpus: 1 paper; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom B. Chowbay trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Magnus Ingelman-Sundberg (in Pharmacology)
  2. Ulrich M. Zanger (in Pharmacology)
  3. M. Eichelbaum (in Pharmacology)
  4. Richard M. Weinshilboum (in Pharmacology)

Papers from B. Chowbay's perspective

Ordered by how strongly the researchers B. Chowbay trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6… (Journal of Pharmacology and Experimental Therapeutics)
  2. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients (AIDS (London))
  3. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. (Pharmacogenetics (London))
  4. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression (Nature Genetics)
  5. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. (The Lancet)
  6. Drug metabolism and variability among patients in drug response. (New England Journal of Medicine)
  7. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism (Clinical Pharmacokinetics)
  8. Clinical importance of the cytochromes P450. (The Lancet)
  9. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Clinical pharmacology and therapy)
  10. Inheritance and drug response. (New England Journal of Medicine)

Their papers